新兴胰岛素技术在基层医疗中糖尿病胰岛素治疗起始及强化治疗中的作用
Role of Emerging Insulin Technologies in the Initiation and Intensification of Insulin Therapy for Diabetes in Primary Care.
作者信息
Brunton Stephen A, Kruger Davida F, Funnell Martha M
机构信息
Primary Care Metabolic Group, Charlotte, NC.
Henry Ford Health System Division of Endocrinology, Diabetes, Bone and Mineral Disease, Detroit, MI.
出版信息
Clin Diabetes. 2016 Jan;34(1):34-43. doi: 10.2337/diaclin.34.1.34.
Abstract
In Brief This article explores some of the reasons for the delay in insulin initiation in primary care and evaluates new approaches to insulin therapy that may address these barriers and, therefore, improve insulin use by primary care providers.
摘要
简而言之，本文探讨了初级保健中胰岛素起始延迟的一些原因，并评估了胰岛素治疗的新方法，这些方法可能消除这些障碍，从而提高初级保健提供者对胰岛素的使用。
相似文献
1
Role of Emerging Insulin Technologies in the Initiation and Intensification of Insulin Therapy for Diabetes in Primary Care.
Clin Diabetes. 2016 Jan;34(1):34-43. doi: 10.2337/diaclin.34.1.34.
2
Identification of barriers to insulin therapy and approaches to overcoming them.
Diabetes Obes Metab. 2018 Mar;20(3):488-496. doi: 10.1111/dom.13132. Epub 2017 Nov 22.
3
Therapeutic Inertia and Delays in Insulin Intensification in Type 2 Diabetes: A Literature Review.
Diabetes Spectr. 2023 Fall;36(4):379-384. doi: 10.2337/ds22-0084. Epub 2023 Jun 23.
4
Barriers and Attitudes of Primary Healthcare Physicians to Insulin Initiation and Intensification in Saudi Arabia.
Int J Environ Res Public Health. 2022 Dec 14;19(24):16794. doi: 10.3390/ijerph192416794.
5
Approaches to rapid acting insulin intensification in patients with type 2 diabetes mellitus not achieving glycemic targets.
Ann Med. 2018 Sep;50(6):453-460. doi: 10.1080/07853890.2018.1493216. Epub 2018 Aug 25.
6
Consensus on "Basal insulin in the management of Type 2 Diabetes: Which, When and How?".
J Assoc Physicians India. 2017 Jul;65(7):51-62.
7
Addressing barriers to initiation of insulin in patients with type 2 diabetes.
Prim Care Diabetes. 2010 Apr;4 Suppl 1:S11-8. doi: 10.1016/S1751-9918(10)60004-6.
8
An exploratory trial of insulin initiation and titration among patients with type 2 diabetes in the primary care setting with retrospective continuous glucose monitoring as an adjunct: INITIATION study protocol.
BMC Fam Pract. 2014 May 3;15:82. doi: 10.1186/1471-2296-15-82.
9
Ethnic disparities in initiation and intensification of diabetes treatment in adults with type 2 diabetes in the UK, 1990-2017: A cohort study.
PLoS Med. 2020 May 15;17(5):e1003106. doi: 10.1371/journal.pmed.1003106. eCollection 2020 May.
10
Early treatment with dipeptidyl-peptidase 4 inhibitors reduces glycaemic variability and delays insulin initiation in type 2 diabetes: A propensity score-matched cohort study.
Diabetes Metab Res Rev. 2024 Jan;40(1):e3711. doi: 10.1002/dmrr.3711. Epub 2023 Aug 26.
引用本文的文献
1
Insulin Initiation and Titration in Patients With Type 2 Diabetes.
Diabetes Spectr. 2019 May;32(2):104-111. doi: 10.2337/ds18-0005.
本文引用的文献
1
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
Diabetes Obes Metab. 2015 Apr;17(4):386-94. doi: 10.1111/dom.12438. Epub 2015 Feb 12.
2
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Diabetes Care. 2015 Jan;38(1):140-9. doi: 10.2337/dc14-2441.
3
Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
Diabetes Obes Metab. 2015 Mar;17(3):261-7. doi: 10.1111/dom.12416. Epub 2015 Jan 7.
4
Weight change in patients with type 2 diabetes starting basal insulin therapy: correlates and impact on outcomes.
Postgrad Med. 2014 Oct;126(6):93-105. doi: 10.3810/pgm.2014.10.2824.
5
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
Diabetes Care. 2014 Dec;37(12):3235-43. doi: 10.2337/dc14-0990. Epub 2014 Sep 5.
6
New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1.
Diabetes Care. 2015 Apr;38(4):637-43. doi: 10.2337/dc14-0006. Epub 2014 Aug 22.
7
Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials.
Diabetes Ther. 2014 Dec;5(2):435-46. doi: 10.1007/s13300-014-0076-9. Epub 2014 Aug 1.
8
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).
Diabetes Care. 2014 Oct;37(10):2755-62. doi: 10.2337/dc14-0991. Epub 2014 Jul 30.
9
Effects of telephone-based peer support in patients with type 2 diabetes mellitus receiving integrated care: a randomized clinical trial.
JAMA Intern Med. 2014 Jun;174(6):972-81. doi: 10.1001/jamainternmed.2014.655.
10
Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml.
Diabetes Obes Metab. 2014 Sep;16(9):873-6. doi: 10.1111/dom.12283. Epub 2014 Mar 24.
Zotero 插件